Truist Securities Downgrades Longboard Pharmaceuticals to Hold, Maintains Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has downgraded Longboard Pharmaceuticals from Buy to Hold, while maintaining the price target at $60.
October 15, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities downgraded Longboard Pharmaceuticals from Buy to Hold, maintaining the price target at $60. This suggests a neutral outlook on the stock.
The downgrade from Buy to Hold indicates a shift from a positive to a neutral stance by Truist Securities, suggesting that the stock may not outperform in the short term. However, the maintained price target of $60 implies that the analyst still sees value at the current price level.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100